Background:Retinal ganglion cell(RGC)death caused by acute ocular hypertension is an important characteristic of acute glaucoma.Receptor-interacting protein kinase 3(RIPK3)that mediates necroptosis is a potential ther...Background:Retinal ganglion cell(RGC)death caused by acute ocular hypertension is an important characteristic of acute glaucoma.Receptor-interacting protein kinase 3(RIPK3)that mediates necroptosis is a potential therapeutic target for RGC death.However,the current understanding of the targeting agents and mechanisms of RIPK3 in the treatment of glaucoma remains limited.Notably,artificial intelligence(AI)technologies have significantly advanced drug discovery.This study aimed to discover RIPK3 inhibitor with AI assistance.Methods:An acute ocular hypertension model was used to simulate pathological ocular hypertension in vivo.We employed a series of AI methods,including large language and graph neural network models,to identify the target compounds of RIPK3.Subsequently,these target candidates were validated using molecular simulations(molecular docking,absorption,distribution,metabolism,excretion,and toxicity[ADMET]prediction,and molecular dynamics simulations)and biological experiments(Western blotting and fluorescence staining)in vitro and in vivo.Results:AI-driven drug screening techniques have the potential to greatly accelerate drug development.A compound called HG9-91-01,identified using AI methods,exerted neuroprotective effects in acute glaucoma.Our research indicates that all five candidates recommended by AI were able to protect the morphological integrity of RGC cells when exposed to hypoxia and glucose deficiency,and HG9-91-01 showed a higher cell survival rate compared to the other candidates.Furthermore,HG9-91-01 was found to protect the retinal structure and reduce the loss of retinal layers in an acute glaucoma model.It was also observed that the neuroprotective effects of HG9-91-01 were highly correlated with the inhibition of PANoptosis(apoptosis,pyroptosis,and necroptosis).Finally,we found that HG9-91-01 can regulate key proteins related to PANoptosis,indicating that this compound exerts neuroprotective effects in the retina by inhibiting the expression of proteins related to apoptosis,pyroptosis,and necroptosis.Conclusion:AI-enabled drug discovery revealed that HG9-91-01 could serve as a potential treatment for acute glaucoma.展开更多
基金supported by grants from the Guangzhou National Laboratory(No.YW-SLJC0201)Macao Young Scholar Program(No.AM2023024).
文摘Background:Retinal ganglion cell(RGC)death caused by acute ocular hypertension is an important characteristic of acute glaucoma.Receptor-interacting protein kinase 3(RIPK3)that mediates necroptosis is a potential therapeutic target for RGC death.However,the current understanding of the targeting agents and mechanisms of RIPK3 in the treatment of glaucoma remains limited.Notably,artificial intelligence(AI)technologies have significantly advanced drug discovery.This study aimed to discover RIPK3 inhibitor with AI assistance.Methods:An acute ocular hypertension model was used to simulate pathological ocular hypertension in vivo.We employed a series of AI methods,including large language and graph neural network models,to identify the target compounds of RIPK3.Subsequently,these target candidates were validated using molecular simulations(molecular docking,absorption,distribution,metabolism,excretion,and toxicity[ADMET]prediction,and molecular dynamics simulations)and biological experiments(Western blotting and fluorescence staining)in vitro and in vivo.Results:AI-driven drug screening techniques have the potential to greatly accelerate drug development.A compound called HG9-91-01,identified using AI methods,exerted neuroprotective effects in acute glaucoma.Our research indicates that all five candidates recommended by AI were able to protect the morphological integrity of RGC cells when exposed to hypoxia and glucose deficiency,and HG9-91-01 showed a higher cell survival rate compared to the other candidates.Furthermore,HG9-91-01 was found to protect the retinal structure and reduce the loss of retinal layers in an acute glaucoma model.It was also observed that the neuroprotective effects of HG9-91-01 were highly correlated with the inhibition of PANoptosis(apoptosis,pyroptosis,and necroptosis).Finally,we found that HG9-91-01 can regulate key proteins related to PANoptosis,indicating that this compound exerts neuroprotective effects in the retina by inhibiting the expression of proteins related to apoptosis,pyroptosis,and necroptosis.Conclusion:AI-enabled drug discovery revealed that HG9-91-01 could serve as a potential treatment for acute glaucoma.
